Exclusive Gene Patents Can Hurt Competition: Study

Law360, New York (April 14, 2010, 5:12 PM EDT) -- Exclusive licenses for gene patents tend to limit innovation and competition for tests that can show people whether they carry genes for certain hereditary diseases, according to new studies from researchers at the Duke Institute for Genome Sciences & Policy.

The restrictive licensing practices that academic institutions holding gene patents often use can keep other universities from creating alternative tests that would prove more accurate or possibly even lower patient costs, Duke researchers said in a series of case studies published Wednesday in a special edition...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.